JERUSALEM, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences.
| Event: | Citi’s 2023 Annual BioPharma Conference |
| Format: | 1-on-1 meetings |
| Date: | September 6th, 2023 |
| Location: | Boston, MA |
| Event: | Emerging Growth Conference |
| Format: | Company presentation and 1-on-1 meetings |
| Date: | September 7th, 2023 |
| Time | 2:20 – 2:50 PM ET |
| Location: | Virtual |
| Event: | Cantor Fitzgerald Global Healthcare Conference |
| Format: | Fireside chat and 1-on-1 meetings |
| Date: | September 27th, 2023 |
| Time: | 3:35 – 4:05 PM ET |
| Location: | New York, NY |
Please reach out to your Citi and Cantor representatives to schedule, and register here to ensure you are able to attend the Emerging Growth conference and receive any updates that are released.
If attendees are not able to join the Emerging Growth Conference live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.
About Alpha Tau Medical, Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Investor Relations Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.57 |
| Daily Change: | 0.04 1.58 |
| Daily Volume: | 4,921 |
| Market Cap: | US$180.160M |
April 02, 2025 March 12, 2025 January 27, 2025 December 18, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
